Literature DB >> 17996559

High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction.

Marianne Zeller1, David Masson, Michel Farnier, Luc Lorgis, Valérie Deckert, Jean-Paul Pais de Barros, Catherine Desrumaux, Pierre Sicard, Jacques Grober, Denis Blache, Philippe Gambert, Luc Rochette, Yves Cottin, Laurent Lagrost.   

Abstract

OBJECTIVES: Our aim was to characterize cholesteryl ester transfer protein (CETP) activity in the early phase of acute myocardial infarction (MI).
BACKGROUND: Cholesteryl ester transfer protein catalyzes the transfer of cholesteryl esters from high-density lipoprotein (HDL) donors to apolipoprotein B-containing lipoprotein acceptors.
METHODS: The CETP concentration, lipid profiles, and the rate of cholesteryl ester transfer (CET) from a tracer dose of radiolabeled HDL toward endogenous lipoproteins were determined within 24 h after symptom onset.
RESULTS: Among 347 patients with first MI, CETP concentration, triglycerides, and non-HDL-cholesterol increased across tertiles of the CET rate, whereas HDL-cholesterol, HDL, and LDL sizes decreased gradually. Among lipoprotein donors and acceptors, the best predictors of the CET rate were HDL2b and non-HDL-cholesterol, respectively. Mean age at first MI was 8.5 years lower in the patients from the highest CET tertile than in those in the lowest CET tertile. Diagonal stratification according to both non-HDL-cholesterol and HDL2b tertiles revealed that patients in the highest CET group were 18 years younger than patients in the lowest CET group. Parameters of the high CETP mass/high non-HDL-cholesterol/low HDL2b triad were independently associated with the CET rate.
CONCLUSIONS: In patients with acute MI, high CET rates are characterized by the presence of the high CETP mass/high non-HDL-cholesterol/low HDL2b triad. The association of high CET rates with young age at first MI lends support to a significant contribution of CETP to the accelerated progression of disease among asymptomatic patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17996559     DOI: 10.1016/j.jacc.2007.06.052

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

1.  Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?

Authors:  Patrick Duriez
Journal:  Curr Atheroscler Rep       Date:  2008-06       Impact factor: 5.113

2.  Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease.

Authors:  Xavier Pillois; Thomas Gautier; Benjamin Bouillet; Jean-Paul Pais de Barros; Aline Jeannin; Bruno Vergès; Jacques Bonnet; Laurent Lagrost
Journal:  J Lipid Res       Date:  2012-04-02       Impact factor: 5.922

3.  Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice.

Authors:  Thomas Gautier; Willeke de Haan; Jacques Grober; Dan Ye; Matthias J Bahr; Thierry Claudel; Niels Nijstad; Theo J C Van Berkel; Louis M Havekes; Michael P Manns; Stefan M Willems; Pancras C W Hogendoorn; Laurent Lagrost; Folkert Kuipers; Miranda Van Eck; Patrick C N Rensen; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2013-04-25       Impact factor: 5.922

4.  Circulating plasma cholesteryl ester transfer protein activity and blood pressure tracking in the community.

Authors:  Justin P Zachariah; Michael J Pencina; Asya Lyass; Guneet Kaur; Ralph B D'Agostino; Jose M Ordovas; Ramachandran S Vasan
Journal:  J Hypertens       Date:  2011-05       Impact factor: 4.844

5.  Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study.

Authors:  Sander J Robins; Asya Lyass; Robert W Brocia; Joseph M Massaro; Ramachandran S Vasan
Journal:  Atherosclerosis       Date:  2013-02-18       Impact factor: 5.162

Review 6.  CETP Inhibition in CVD Prevention: an Actual Appraisal.

Authors:  Belinda Di Bartolo; Kohei Takata; MyNgan Duong; Stephen J Nicholls
Journal:  Curr Cardiol Rep       Date:  2016-05       Impact factor: 2.931

7.  Females with angina pectoris have altered lipoprotein metabolism with elevated cholesteryl ester transfer protein activity and impaired high-density lipoproteins-associated antioxidant enzymes.

Authors:  Jungho Park; Jae-Ryong Kim; Dong-Gu Shin; Kyung-Hyun Cho
Journal:  Int J Mol Med       Date:  2011-12-29       Impact factor: 4.101

Review 8.  Low-normal thyroid function and novel cardiometabolic biomarkers.

Authors:  Lynnda J N van Tienhoven-Wind; Robin P F Dullaart
Journal:  Nutrients       Date:  2015-02-16       Impact factor: 5.717

9.  Hibernating brown bears are protected against atherogenic dyslipidemia.

Authors:  Chantal Simon; Stéphane Blanc; Sylvain Giroud; Isabelle Chery; Mathilde Arrivé; Michel Prost; Julie Zumsteg; Dimitri Heintz; Alina L Evans; Guillemette Gauquelin-Koch; Jon M Arnemo; Jon E Swenson; Etienne Lefai; Fabrice Bertile
Journal:  Sci Rep       Date:  2021-09-21       Impact factor: 4.379

10.  High levels of asymmetric dimethylarginine are strongly associated with low HDL in patients with acute myocardial infarction.

Authors:  Julie Lorin; Jean-Claude Guilland; Claudia Korandji; Claude Touzery; Florence Bichat; Aline Chagnon; Yves Cottin; Luc Rochette; Catherine Vergely; Marianne Zeller
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.